Pengaruh Recombinant Human Erythropoietin terhadap Jumlah Osteoblas, Osteoklas dan kadar Hemoglobin pada Penyembuhan Fraktur Tulang Mandibula Studi Eksperimental pada Fraktur Mandibula Tikus Sprague-Dawley

Abstract

Recombinant human erythropoietin (rHuEPO) is usually used as treatment choice for anemia due to end stage renal disease, but RHuEPO has reseptor in other tissues, so it has non erythroid effect. Its benefits in bone healing is still debated. This
study aims to determine the effect of rHuEPO on the number of osteoblasts, osteoclasts and hemoglobin level in mandible fracture healing model.A controlled incomplete fracture mandibular symphysis was created surgically in twenty subjects of Sprague-Dawley rats. Ten subjects treatment group receive subcutaneous injection of 40 IU rHuEPO alpha for seven days, while ten subjects control
got NaCl 0.9%. Hemoglobin of five subjects treatment group and five control were examined, then decapitated for HE histological evaluation on 7^th and 14^th
day respectively. ANOVA and Paired T-test for hemoglobin data analysis based on study day, while the T-Independent test for number osteoblasts and osteoclast data based on study group.There were a significant difference on number
of osteoblasts and osteoclasts 7^th day compared to 14^th day (p<0.05). Based on group, it revealed a significant difference in the number of osteoblasts (p=0.003), osteoclasts (p = 0.011) on 7^th day, and osteoclasts number (p = 0.001) 14^th day. Hemoglobin on 7^th day had a significant difference compared to day 0 (p=0,001^a and p=0,000^b). Administration of rHuEPO enhance the number
of osteoblasts and osteoclasts as well as hemoglobin on 7^th day. On 14^th day, only osteoclast number’s had significant difference and hemoglobin returned to baseline.